Related Experiment Video
Updated: Jun 2, 2025
Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
MIR-155 as a potential biomarker for disease severity in st-segment elevation myocardial infarction: insights from a
Ailyn Morales-Rentería1, Amina Ruiz-Santos1, Luis M Amezcua-Castillo2
1School of Medicine, Universidad Autónoma Metropolitana (UAM)-Xochimilco, Mexico City, Mexico.
Background:
MiR-155 plays a role in inflammatory pathways and cardiovascular diseases, though its relationship with inflammation, atherosclerosis, and outcomes in ST-elevation myocardial infarction (STEMI) is not well established.
Objective:
To investigate associations between miR-155 levels, inflammation, atherosclerotic burden, and major adverse cardiovascular events (MACE) in STEMI patients.
Methods:
Sixty-nine STEMI patients and 16 healthy controls were recruited from a specialized university-affiliated cardiovascular center. MiR-155 expression and serum interleukin (IL)-1β, IL-6, and tumor necrosis factor levels were measured. Patients were grouped into tertiles based on miR-155 expression. Clinical data, atherosclerotic burden (through cardiac catheterization), and in-hospital MACE were recorded.
Results:
MiR-155 levels were significantly lower in STEMI patients compared to controls (median 54.2, vs. 152.8 arbitrary units; p = 0.003). Higher miR-155 tertiles were associated with a greater prevalence of three-vessel occlusion (34% vs. 13% vs. 4%; p = 0.007) and increased incidence of pulmonary edema (13% vs. 0% vs. 0%; p = 0.030). No significant correlation was found between miR-155 and inflammatory or myocardial markers.
Conclusion:
Dysregulated miR-155 expression in STEMI patients may influence disease severity and MACE risk, independent of inflammation or myocardial damage markers.
Insights
MicroRNA-155 (miR-155) levels are lower in ST-elevation myocardial infarction (STEMI) patients and linked to more severe atherosclerosis and adverse outcomes, independent of inflammation.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biomarker Discovery
Background:
- MicroRNA-155 (miR-155) is implicated in inflammatory processes and cardiovascular diseases.
- Its specific role in ST-elevation myocardial infarction (STEMI), including associations with inflammation, atherosclerosis, and clinical outcomes, requires further elucidation.
Purpose of the Study:
- To investigate the relationship between miR-155 expression levels and markers of inflammation, atherosclerotic burden, and major adverse cardiovascular events (MACE) in patients with STEMI.
Main Methods:
- A cohort of 69 STEMI patients and 16 healthy controls underwent miR-155 expression analysis and serum inflammatory marker measurement.
- Patients were stratified into tertiles based on miR-155 levels, with clinical data, atherosclerotic burden via cardiac catheterization, and in-hospital MACE meticulously recorded.
Main Results:
- STEMI patients exhibited significantly lower miR-155 levels compared to controls (median 54.2 vs. 152.8 arbitrary units; p = 0.003).
- Higher miR-155 expression tertiles correlated with increased prevalence of three-vessel coronary artery occlusion (p = 0.007) and a higher incidence of pulmonary edema (p = 0.030).
- No significant associations were observed between miR-155 levels and inflammatory markers or myocardial damage indicators.
Conclusions:
- Dysregulated miR-155 expression in STEMI patients may contribute to disease severity and MACE risk.
- These effects appear to be independent of established markers of inflammation or myocardial injury.
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
